Medpace (MEDP) ended the recent trading session at $487.95, demonstrating a -1.88% change from the preceding day's closing price. The stock fell short of the S&P 500, which registered a loss of 0.5% for the day. Meanwhile, the Dow experienced a drop of 0.38%, and the technology-dominated Nasdaq saw a decrease of 0.5%.
Shares of the provider of outsourced clinical development services have appreciated by 5.04% over the course of the past month, outperforming the Medical sector's loss of 0.7%, and the S&P 500's gain of 2.74%.
Market participants will be closely following the financial results of Medpace in its upcoming release. The company plans to announce its earnings on October 22, 2025. It is anticipated that the company will report an EPS of $3.49, marking a 15.95% rise compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $640.76 million, indicating a 20.14% upward movement from the same quarter last year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $13.99 per share and a revenue of $2.46 billion, signifying shifts of +10.77% and +16.83%, respectively, from the last year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Medpace. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Currently, Medpace is carrying a Zacks Rank of #3 (Hold).
With respect to valuation, Medpace is currently being traded at a Forward P/E ratio of 35.55. This valuation marks a premium compared to its industry average Forward P/E of 16.94.
Investors should also note that MEDP has a PEG ratio of 3.13 right now. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. MEDP's industry had an average PEG ratio of 1.68 as of yesterday's close.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 98, which puts it in the top 40% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Medpace Holdings, Inc. (MEDP): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
